K-numberK243172
Device nameHalyard Purple Nitrile* Powder-Free Exam Gloves, Sterile Pairs; Halyard Purple Nitrile* Powder-Free Exam Gloves, Sterile Singles
ApplicantO&M Halyard, Inc.
Product codeLZA
Device classClass I
Decision dateJun 18, 2025
DecisionSubstantially Equivalent
Regulation880.6250
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Halyard Purple Nitrile Powder-Free Exam Gloves are disposable, sterile, purple-colored nitrile examination gloves intended to prevent contamination between patient and examiner. They have been tested for use with numerous chemotherapy drugs, fentanyl citrate, and simulated gastric acid, with no breakthrough detected for most substances up to 240 minutes.

Technological characteristics

The subject device is a 9.5-inch, chlorinated, nitrile, powder-free, textured fingertip, ambidextrous, sterile glove available in sizes S, M, and L. It shares the same construction characteristics (color, material, sterilization, texture) as the predicate device, with comparable physical properties including tensile strength, elongation, and thickness specifications meeting ASTM D6319 standards.

Test standards cited

ASTM D6978-05 (chemotherapy drug permeation resistance); ASTM D6319-10 (nitrile glove specifications for physical properties and dimensions); ASTM D5151-06 (pinhole detection); ASTM D6124-06 (residual powder); ISO 10993 Parts 10, 11, and 23 (biocompatibility: irritation, acute systemic toxicity, and skin sensitization); ANSI/AAMI/ISO 11137 (sterility).

Substantial equivalence argument

The subject device demonstrates substantial equivalence because it is identical in design, materials, construction, and intended use to the predicate device (K102032). Both are sterile, powder-free, purple nitrile gloves with identical technological characteristics and sizing. Non-clinical testing shows the subject device meets all acceptance criteria for the same standards as the predicate, including physical properties, biocompatibility, and importantly, chemotherapy drug permeation resistance for 51 drugs tested with no breakthrough at 240 minutes, supporting the same indications for use with chemotherapy drugs.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →